Cytokinetics Inc vs Norfolk Southern Corporation — how do they compare? Cytokinetics Inc trades at $76.64 (market cap $10.63B), while Norfolk Southern Corporation trades at $334 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 7.1× Cytokinetics Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | NSC | |
|---|---|---|
Market Cap | $10.63B | $75.15B |
Sector | Technology | Technology |
52-Week High | $87.26 | $350.66 |
52-Week Low | $34.31 | $272.35 |
Enterprise Value | $10.74B | $90.70B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Norfolk Southern (NSC) trades at $332.82, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.52 per share, beating estimates, driven by record revenue and volume growth. Valuation ratios like P/E of 28.55 and P/S of 5.99 indicate a premium, while profitability remains solid with a net income margin of 21.02% and ROE of 16.97%. Recent news highlights merger developments with Union Pacific and institutional interest.
Outlook is cautiously optimistic due to earnings momentum and industry tailwinds, but risks include high fuel costs, merger execution uncertainties, and premium valuation. Analysts give a mixed consensus with 43.75% buy ratings and a $369.67 price target, suggesting modest upside potential from current levels amid competitive and operational headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →